Literature DB >> 19653262

Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer.

Hiroshi Miyata1, Makoto Yamasaki, Shuji Takiguchi, Kiyokazu Nakajima, Yoshiyuki Fujiwara, Toshiro Nishida, Masaki Mori, Yuichiro Doki.   

Abstract

BACKGROUND AND OBJECTIVES: Although locoregional failure frequently occurs after definitive chemoradiotherapy (CRT), the role of salvage esophagectomy has not been fully evaluated. The aim of this study was to compare the outcome of salvage esophagectomy after high-dose definitive CRT with neoadjuvant CRT.
METHODS: From 1994 to 2007, 33 patients with thoracic esophageal cancer underwent salvage esophagectomy after definitive CRT, and 115 patients underwent neoadjuvant CRT followed by surgery.
RESULTS: The postoperative mortality rate in the salvage group (12%) was higher than in the neoadjuvant group (3.6%, P = 0.059). The rates of postoperative complications were significantly higher in the salvage group than in neoadjuvant group: Anastomotic leakage (39% vs. 22%, respectively, P = 0.049), bleeding (15% vs. 1.7%, respectively, P = 0.002), cardiovascular complications (24% vs. 5.4%, respectively, P = 0.001). Univariate analysis showed that pretherapy T stage, pretherapy lymph node status, pathological T stage, and operative curability were significant prognostic factors affecting survival of patients who underwent salvage esophagectomy. In particular, patients with cT3-T4 tumors or cN1 tumors before definitive CRT showed worse prognosis after salvage esophagectomy.
CONCLUSIONS: Salvage esophagectomy after high-dose definitive CRT was associated with higher postoperative mortality and morbidity rates compared with neoadjuvant CRT. Only selected patients can be rescued by salvage esophagectomy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19653262     DOI: 10.1002/jso.21353

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  33 in total

1.  Advantages of salvage photodynamic therapy using talaporfin sodium for local failure after chemoradiotherapy or radiotherapy for esophageal cancer.

Authors:  Tatsunori Minamide; Yusuke Yoda; Keisuke Hori; Kensuke Shinmura; Yasuhiro Oono; Hiroaki Ikematsu; Tomonori Yano
Journal:  Surg Endosc       Date:  2019-05-28       Impact factor: 4.584

2.  Is the outcome of a salvage surgery for T4 thoracic esophageal squamous cell carcinoma really poor?

Authors:  Yasunori Akutsu; Tsuguaki Kono; Masaya Uesato; Isamu Hoshino; Kentaro Murakami; Tomoyoshi Aoyagi; Takumi Ota; Takeshi Toyozumi; Hiroshi Suito; Hiroki Kobayashi; Rintaro Harada; Takashi Uno; Hisahiro Matsubara
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

Review 3.  Photodynamic therapy for esophageal cancer.

Authors:  Tomonori Yano; Ken Hatogai; Hiroyuki Morimoto; Yusuke Yoda; Kazuhiro Kaneko
Journal:  Ann Transl Med       Date:  2014-03

4.  Risk factors for pulmonary complications after esophagectomy for esophageal cancer.

Authors:  Naoya Yoshida; Masayuki Watanabe; Yoshifumi Baba; Shiro Iwagami; Takatsugu Ishimoto; Masaaki Iwatsuki; Yasuo Sakamoto; Yuji Miyamoto; Nobuyuki Ozaki; Hideo Baba
Journal:  Surg Today       Date:  2013-04-14       Impact factor: 2.549

5.  Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.

Authors:  Yuji Akiyama; Takeshi Iwaya; Fumitaka Endo; Takehiro Chiba; Takeshi Takahara; Koki Otsuka; Hiroyuki Nitta; Keisuke Koeda; Masaru Mizuno; Yusuke Kimura; Akira Sasaki
Journal:  Surg Endosc       Date:  2017-06-29       Impact factor: 4.584

6.  Prognostic Factors of Salvage Esophagectomy for Residual or Recurrent Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy.

Authors:  Yuki Kiyozumi; Naoya Yoshida; Takatsugu Ishimoto; Taisuke Yagi; Yuki Koga; Tomoyuki Uchihara; Hiroshi Sawayama; Yukiharu Hiyoshi; Masaaki Iwatsuki; Yoshifumi Baba; Yuji Miyamoto; Masayuki Watanabe; Tomohiko Matsuyama; Natsuo Oya; Hideo Baba
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

Review 7.  Current Status and Future Prospects for Esophageal Cancer Treatment.

Authors:  Makoto Sohda; Hiroyuki Kuwano
Journal:  Ann Thorac Cardiovasc Surg       Date:  2016-12-21       Impact factor: 1.520

8.  Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.

Authors:  Arianna Barbetta; Meier Hsu; Kay See Tan; Dessislava Stefanova; Koby Herman; Prasad S Adusumilli; Manjit S Bains; Matthew J Bott; James M Isbell; Yelena Y Janjigian; Geoffrey Y Ku; Bernard J Park; Abraham J Wu; David R Jones; Daniela Molena
Journal:  J Thorac Cardiovasc Surg       Date:  2018-02-15       Impact factor: 5.209

9.  Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk : Planning study in esophageal carcinoma.

Authors:  K Fakhrian; M Oechsner; S Kampfer; T Schuster; M Molls; H Geinitz
Journal:  Strahlenther Onkol       Date:  2013-02-28       Impact factor: 3.621

10.  Outcomes of lymphadenectomy for lymph node recurrence after esophagectomy or definitive chemoradiotherapy for squamous cell carcinoma of the esophagus.

Authors:  Masayuki Watanabe; Shinji Mine; Kazuhiko Yamada; Hironobu Shigaki; Yoshifumi Baba; Naoya Yoshida; Kiyoshi Kajiyama; Noriko Yamamoto; Takeshi Sano; Hideo Baba
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.